NDC 85477-0330-07: Lidexa 38.8 mg/g Cream, 85 g Pump Bottle
This is a package of 85 g of Lidexa 38.8 mg/g Cream from Oncora Pharma, LLC, first listed with the FDA Feb 2026 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 85477-330-07 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 85477 labeler · 330 product · 07 package
- Package marketed since
- Feb 26, 2026
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Billing quantity
- 85 g per package
- Barcode (UPC)
- 0854770330078
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GPI-14 (Medi-Span): 90150085002005
- RxCUI (RxNorm): 1723991
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Antiarrhythmic class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
- Lidocaine numbs the area where it's applied or injected. Depending on the product, it's used for nerve pain after shingles, minor pain, itching, burns and insect bites, mouth and t...
- Numbness generally starts within about 20 seconds to 1 minute and lasts roughly 5 to 30 minutes. Some products, such as Hilook Blue Gel Anesthetic, list a 15 to 30 minute wait. The...
- Mild reactions include dizziness, drowsiness, nervousness and a brief burning at a patch site. Call for help if you have ringing in the ears, a metallic taste, confusion, twitching...
- Better not to. The toxic effects of local anesthetics add together, and patch labels say not to use them with other topical pain relievers or more than one patch at a time. Ask me...
Patient education
Drug interactions
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 85477-0330-07 You're viewing this Main listing | 85 g in 1 BOTTLE, PUMP | 2026-02-26 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Bruselix Cream 38.8 mg/g 59088-0234-05 | PureTek | 57 g | — | — | FDA listed | — |
| DermacinRx Lidotral 38.8 mg/g 59088-0371-07 | PureTek | 1 tube | — | — | FDA listed | — |
| Lidotran 38.8 mg/g 59088-0483-07 | PureTek | 1 tube | — | — | FDA listed | — |
| Lidexa 38.8 mg/gthis 85477-0330-07 | Oncora | 85 g | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Lidocaine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Oncora Pharma, LLC labeler code 85477
- Hydralyn 2 g/100g Gel NDC 85477-316-28
- Hydroryx Hydrocortisone 2% 2 g/100g Gel NDC 85477-317-28
- Embriva ASCORBIC ACID, CHOLECALCIFEROL, THIAMINE, PYRIDOXAL PHOSPHATE, FOLIC ACID, METHYLCOBALAMIN, CALCIUM CARBONATE, FERROUS GLUCONATE, POTASSIUM IODIDE 2.5 mg; .15 mg; 125 mg; .0125 mg; 1.4 mg; 1 mg; 1 mg; 200 mg; 13 mg Tablet NDC 85477-322-30
- LidoSpra 41.2 mg/mL Spray NDC 85477-325-29
- Lidomar 3 g/100mL Lotion NDC 85477-326-07
- Spravex 41.2 mg/mL Spray NDC 85477-327-29
- Tolfyra Tolnaftate .3 g/30mL Liquid NDC 85477-331-01
- Metavex .125 mg; 1 mg; 500 mg; 425 mg; 225 mg; 135 mg Tablet NDC 85477-503-30
- Folartex Multivitamin 300 ug; 60 mg; 10 ug; 4.5 mg; 26 mg; .28 mg; 1.67 mg; .013 mg; 80 mg Tablet NDC 85477-511-30
- Vitavera 2500 [iU]/1; 30 mg; 30 mg; 400 [iU]/1; 15 [iU]/1; 1 mg; 1 mg; 13 mg; 1 mg; 1000 ug; 4 ug Tablet, Chewable NDC 85477-513-30
- Folyra Multivitamin 300 ug; 60 mg; 10 ug; 4.5 mg; 26 mg; .28 mg; 1.67 mg; .013 mg; 80 mg Tablet NDC 85477-523-30
- Virexa Vitamin C, Vitamin D3, Vitamin B1, Vitamin B6, Vitamin B12, Folic Acid, NADH, Ubiquinone 125 mg; 12.5 ug; 25 mg; 125 mg; 1.667 mg; 1 mg; 5 mg; 50 mg Tablet NDC 85477-606-30
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Lidexa™ is indicated for topical analgesia as directed by a healthcare provider.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION For topical use only. Apply to the affected area 3 to 4 times daily or as directed by a healthcare provider.
⛔ Contraindications ▾
CONTRAINDICATIONS Lidexa™ is contraindicated in patients with known hypersensitivity to lidocaine or any component of the formulation.
⚠️ Warnings ▾
WARNINGS For external use only. Not for ophthalmic use. Avoid contact with eyes. Excessive application may result in increased systemic absorption. Keep out of reach of children.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Localized skin reactions such as redness, irritation, or rash may occur.
🔄 Drug Interactions ▾
Drug Interactions
🤰 Pregnancy ▾
Pregnancy
🧒 Pediatric Use ▾
Pediatric Use
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Lidexa™ (Lidocaine Hydrochloride 38.8 mg/g) is supplied as a white topical cream in a 3 oz (85 g) tube. NDC 85477-330-07
📋 Description ▾
DESCRIPTION Lidexa™ (Lidocaine Hydrochloride) Cream 38.8
⚠️ Precautions ▾
PRECAUTIONS Use only as directed. If irritation occurs, discontinue use and consult a healthcare provider. General Drug Interactions Carcinogenesis, Mutagenesis, Impairment of Fertility Pregnancy Nursing Mothers Pediatric Use
🍼 Nursing Mothers ▾
Nursing Mothers
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL pdp pdp
Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Where does this data come from?
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |